Industry News

• Monsanto ranks no. 28 on the 2010 DiversityInc Top 50 Companies for Diversity(R) list  Monsanto Company has been named to The 2010 DiversityInc Top 50 Companies for Diversity(R) list for its demonstrated use of measurable diversity best practices and results. A total of 449 companies participated this year, up 12 percent from last year.
  Monsanto Company March 10, 2010  
• Medicis increases cash dividend to $0.06 per share  Medicis announced that its Board of Directors declared a quarter-end cash dividend of $0.06 per issued and outstanding share of its Common Stock payable on April 30, 2010, to stockholders of record at the close of business on April 1, 2010.
  Medicis March 10, 2010  
• Abbott receives U.S. FDA approval for new cataract multifocal intraocular lens  Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for the TECNIS(R) Multifocal 1-Piece intraocular lens (IOL) for cataract patients with and without presbyopia.
  Abbott March 10, 2010  
• FDA approves Botox to treat spasticity in flexor muscles of the elbow, wrist and fingers  The U.S. Food and Drug Administration approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.
  FDA March 09, 2010  
• Abbott enhances pharmaceutical pipeline with acquisition of Facet Biotech  Abbott and Facet Biotech announced a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
  Abbott March 09, 2010  
• Vaccinating children against flu helps protect wider community  Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well.
  National Institutes of Health March 09, 2010  
• Bristol-Myers Squibb and AstraZeneca announce the commencement of the SAVOR-TIMI 53  BMS and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA(TM)(saxagliptin).
  Bristol-Myers Squibb Company March 09, 2010  
• Monsanto to break ground on new breeding station in Mississippi  To better serve the needs of southern farmers, Monsanto plans to open a new corn breeding station in Flora, Mississippi. The $2.4 million facility further boosts the company's investment in the South and is a reflection of Monsanto's commitment to continue delivering new high-performing products.
  Monsanto Company March 09, 2010  
• Sanofi-aventis and Merck to create a global leader in Animal Health  Sanofi-aventis and Merck & Co. announced that sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck's Animal Health business, to create a global leader in Animal Health.
  Merck & Co., Inc. March 09, 2010  
• Novel gene expression test, PROLARIS(TM), accurately predicts prostate cancer recurrence  Myriad Genetics said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS(TM), was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
  Myriad Genetics, Inc. March 08, 2010  

   (next 10 articles)